金隅集團(601992.SH):北京檢驗取得同意在全國中小企業股份轉讓系統掛牌函
格隆匯12月30日丨金隅集團(601992.SH)公佈,公司(以下簡稱“公司”“金隅集團”)控股子公司北京建築材料檢驗研究院股份有限公司(簡稱“北京檢驗”)於近日收到全國中小企業股份轉讓系統有限責任公司出具的《關於同意北京建築材料檢驗研究院股份有限公司股票在全國中小企業股份轉讓系統掛牌的函》(股轉函[2022]3852號),同意北京檢驗股票在全國中小企業股份轉讓系統掛牌公開轉讓,交易方式為集合競價交易。
北京檢驗申請掛牌時股東人數未超過200人,按規定中國證監會豁免核准北京檢驗股票公開轉讓,北京檢驗掛牌後納入非上市公眾公司監管。北京檢驗將按照有關規定辦理掛牌、報備等手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.